Dextromethorphan-Bupropion
PreclinicalSmall molecule
Dextromethorphan-Bupropion is one of 47 small molecule programs targeting Major Depressive Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Aticaprant
Johnson & JohnsonPhase 3
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPhase 3
CYB003
CCybin IRL Limited
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dextromethorphan-Bupropion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAsad Ullah Jan